Laboratorio Reig Jofre, S.A. (FRA:FEQ1)
Germany · Delayed Price · Currency is EUR 2.640
0.00 (0.00%)
Last updated: Jan 20, 2026, 3:25 PM CET
Laboratorio Reig Jofre Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 330.34 | 341.37 | 317.95 | 274.21 | 239.87 | 233.76 | |
Revenue Growth (YoY) | -1.00% | 7.36% | 15.95% | 14.32% | 2.61% | 13.57% |
Cost of Revenue | 139.83 | 147.92 | 141.06 | 119.12 | 96.9 | 94.93 |
Gross Profit | 190.51 | 193.45 | 176.89 | 155.09 | 142.97 | 138.83 |
Selling, General & Admin | 104.29 | 100.78 | 89.79 | 81.87 | 73.9 | 75.55 |
Other Operating Expenses | 53.07 | 54.58 | 51.96 | 42.79 | 41.75 | 36.74 |
Operating Expenses | 181.22 | 178.71 | 164.9 | 145.72 | 133.7 | 129.27 |
Operating Income | 9.29 | 14.73 | 11.99 | 9.37 | 9.28 | 9.57 |
Interest Expense | -1.13 | -1 | -0.75 | -0.69 | -0.68 | -0.68 |
Interest & Investment Income | 0.29 | 0.29 | 0.06 | 0.1 | 0.05 | 0.03 |
Earnings From Equity Investments | -1.14 | -0.12 | 0.98 | 1.59 | 0.09 | 0.09 |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | 0.07 | 0.06 | -0.36 | 0.07 |
Other Non Operating Income (Expenses) | 0.31 | 0.29 | -0.15 | -0.7 | -2.15 | -2.29 |
EBT Excluding Unusual Items | 7.63 | 14.2 | 12.21 | 9.74 | 6.23 | 6.79 |
Impairment of Goodwill | -1 | -1 | - | -0.4 | - | - |
Gain (Loss) on Sale of Assets | -1.38 | -1.38 | -0.72 | -0.57 | -0.44 | -0.36 |
Asset Writedown | -0.64 | - | -1 | - | 0 | - |
Pretax Income | 4.61 | 11.82 | 10.5 | 8.76 | 5.79 | 6.43 |
Income Tax Expense | 0.27 | 1.36 | 1.1 | 0.66 | 0.71 | 0.76 |
Earnings From Continuing Operations | 4.34 | 10.47 | 9.4 | 8.11 | 5.08 | 5.67 |
Minority Interest in Earnings | -0.09 | -0.09 | 0.01 | 0 | 0.01 | 0.01 |
Net Income | 4.25 | 10.38 | 9.41 | 8.11 | 5.09 | 5.67 |
Net Income to Common | 4.25 | 10.38 | 9.41 | 8.11 | 5.09 | 5.67 |
Net Income Growth | -55.51% | 10.37% | 16.04% | 59.21% | -10.23% | 14.77% |
Shares Outstanding (Basic) | 81 | 80 | 80 | 79 | 78 | 77 |
Shares Outstanding (Diluted) | 81 | 80 | 80 | 79 | 78 | 77 |
Shares Change (YoY) | - | -0.01% | 1.50% | 1.32% | 1.13% | 7.99% |
EPS (Basic) | 0.05 | 0.13 | 0.12 | 0.10 | 0.07 | 0.07 |
EPS (Diluted) | 0.05 | 0.13 | 0.12 | 0.10 | 0.07 | 0.07 |
EPS Growth | - | 10.37% | 17.49% | 52.89% | -6.56% | 0.97% |
Free Cash Flow | - | 11.08 | 6.65 | 5.2 | -4.73 | 6.75 |
Free Cash Flow Per Share | - | 0.14 | 0.08 | 0.07 | -0.06 | 0.09 |
Dividend Per Share | - | 0.049 | 0.040 | 0.040 | 0.040 | 0.045 |
Dividend Growth | - | 22.50% | - | - | -11.11% | - |
Gross Margin | 57.67% | 56.67% | 55.63% | 56.56% | 59.60% | 59.39% |
Operating Margin | 2.81% | 4.32% | 3.77% | 3.42% | 3.87% | 4.09% |
Profit Margin | 1.29% | 3.04% | 2.96% | 2.96% | 2.12% | 2.43% |
Free Cash Flow Margin | - | 3.25% | 2.09% | 1.90% | -1.97% | 2.89% |
EBITDA | 25.7 | 31.1 | 28.3 | 22.56 | 20.36 | 20.32 |
EBITDA Margin | 7.78% | 9.11% | 8.90% | 8.23% | 8.49% | 8.69% |
D&A For EBITDA | 16.41 | 16.37 | 16.31 | 13.19 | 11.08 | 10.75 |
EBIT | 9.29 | 14.73 | 11.99 | 9.37 | 9.28 | 9.57 |
EBIT Margin | 2.81% | 4.32% | 3.77% | 3.42% | 3.87% | 4.09% |
Effective Tax Rate | 5.92% | 11.46% | 10.47% | 7.51% | 12.31% | 11.83% |
Advertising Expenses | - | 11.96 | 12.96 | 10.99 | 9 | 8.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.